Abstract
Seventy-three patients with stage C and D prostatic carcinoma were treated with hormonotherapy. During a mean follow-up of 27 +/- 17.8 months, 30 tumour-related deaths were registered. The patients in the G3 subset suffered a 35.7% early death rate versus a 10.1% rate of G1-2 ones. This difference is significant (p = 0.0102). Nevertheless the Authors' opinion is that G3 patients should not be given a more aggressive treatment initially apart from the case of a controlled trial.
Publication types
-
Comparative Study
-
English Abstract
MeSH terms
-
Aged
-
Aged, 80 and over
-
Carcinoma / drug therapy
-
Carcinoma / mortality*
-
Carcinoma / pathology
-
Carcinoma / surgery
-
Combined Modality Therapy
-
Flutamide / therapeutic use*
-
Goserelin / therapeutic use*
-
Humans
-
Life Tables
-
Male
-
Middle Aged
-
Neoplasm Staging
-
Orchiectomy
-
Prostatic Neoplasms / drug therapy
-
Prostatic Neoplasms / mortality*
-
Prostatic Neoplasms / pathology
-
Prostatic Neoplasms / surgery
-
Survival Analysis
-
Survival Rate